Keyphrases
Real-world Experience
100%
Multicenter Retrospective Study
100%
Relapsed or Refractory multiple Myeloma
100%
Belantamab Mafodotin
100%
Confidence Interval
80%
Monotherapy
40%
Multiple Myeloma Patients
40%
Heavily Pretreated
40%
Adverse Effects
20%
Thrombocytopenia
20%
Agent Behavior
20%
Prospective Clinical Trial
20%
Follow-up Time
20%
Immunoconjugate
20%
Toxicity Profile
20%
Care Program
20%
Expanded Access
20%
Blurred Vision
20%
Phase 1 Study
20%
Overall Response Rate
20%
Median Overall Survival
20%
Median Progression-free Survival
20%
Phase II Study
20%
Keratopathy
20%
Ocular Toxicity
20%
Compassionate Care
20%
B-cell Maturation Antigen
20%
Medicine and Dentistry
Retrospective Study
100%
Multiple Myeloma
100%
Belantamab Mafodotin
100%
Monotherapy
40%
Infection
20%
Immunoglobulin
20%
Clinical Trial
20%
Thrombocytopenia
20%
Overall Survival
20%
Conjugate
20%
Glycogen Synthase Kinase
20%
Progression Free Survival
20%
Bullous Keratopathy
20%
Blurred Vision
20%
B Cell Maturation Antigen
20%
Eye Toxicity
20%
Adverse Effect
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Retrospective Study
100%
Belantamab Mafodotin
100%
Monotherapy
40%
Clinical Trial
20%
Infection
20%
Progression Free Survival
20%
Overall Survival
20%
Immunoglobulin
20%
Glycogen Synthase Kinase
20%
Thrombocytopenia
20%
Blurred Vision
20%
Eye Toxicity
20%
Keratopathy
20%
B Cell Maturation Antigen
20%